Citius Pharmaceuticals Inc
NASDAQ:CTXR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Suzhou Dongshan Precision Manufacturing Co Ltd
SZSE:002384
|
CN |
|
Suzhou TFC Optical Communication Co Ltd
SZSE:300394
|
CN |
Citius Pharmaceuticals Inc
Total Current Assets
Citius Pharmaceuticals Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
Total Current Assets
$37.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
47%
|
CAGR 10-Years
62%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Assets
$55.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Assets
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Assets
$42.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Assets
$43.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Assets
$55.6B
|
CAGR 3-Years
46%
|
CAGR 5-Years
26%
|
CAGR 10-Years
16%
|
|
Citius Pharmaceuticals Inc
Glance View
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 15 full-time employees. The company went IPO on 2017-08-03. The firm develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. The company has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
See Also
What is Citius Pharmaceuticals Inc's Total Current Assets?
Total Current Assets
37.9m
USD
Based on the financial report for Dec 31, 2025, Citius Pharmaceuticals Inc's Total Current Assets amounts to 37.9m USD.
What is Citius Pharmaceuticals Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
62%
Over the last year, the Total Current Assets growth was 107%. The average annual Total Current Assets growth rates for Citius Pharmaceuticals Inc have been -4% over the past three years , 47% over the past five years , and 62% over the past ten years .
